CureVac highlights shift to mRNA technology in seasonal influenza vaccine development: GlobalData
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
The inspection was a cGMP Inspection and had ended with NIL observations
The non-enzymatic electrochemical sensing strip can simultaneously detect the direct and total bilirubin in a single drop of blood, and provide the concentrations within a minute
The company will develop and produce premixes for human nutrition applications
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
Eris Lifesciences enters into term loan agreement with Citi Bank
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
AushadhAI is purposefully designed to deliver significant advantages to the pharmaceutical supply chain's key constituents
Subscribe To Our Newsletter & Stay Updated